- Lobbying
- Lobbying by Foundation Consumer Healthcare LLC
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jennifer Walsh | Administrative Assistant, Deputy COS, COS: Rep. Dennis Cardoza; Field Representative: Rep. Vic Fazio; Staff Assistant, Program Director, Executive Assistant: House Democratic Caucus AA; Deputy COS, COS: Rep. Dennis Cardoza; Field Representative: Rep. Vic Fazio; Staff Asst, Program Dir, EA: House Democratic Caucus AA; Deputy COS, COS: Rep. Dennis Cardoza; FieldRepresentative: Rep. Vic Fazio; Staff Asst, Program Dir, EA:House Democratic Caucus |
Dennis Cardoza | Member of Congress 2003-2012 |
Theodore Bornstein | COS Rep. Aspin; COS Sen. Kohl; OSD-DOD |
Scott Klug | Member of Congress 1991-1999 Member of Congress 1991 to 1999 Member of Congress, 1990-1998 |
Jared Rifis | Sen. Susan Collins, 2010-2015; House Committee on Natural Resources, 2015-2020 Legislative Correspondent, Legislative Aide; Legislative Assistant: Sen. Harry Reid Legislative Correspondent, Legislative Aide; LegislativeAssistant: Sen. Harry Reid |
Amy Beard | n/a |
Craig Chick | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: regulations affecting marketing and commercialization of prescription and non-prescription contraceptive drugs..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate